First author [reference] | Number of patients | Histology | CCT | RT | Targeted therapy | RECIST assessment | Blood flow | Blood volume | Mean transit time | Permeability |
---|---|---|---|---|---|---|---|---|---|---|
Wang et al [23] | 35 | Epidermoid Adenocarcinoma | No | Yes | No | Response | ↓ | ↓ | ↑ | ↓ p > 0.05 |
Wang et al [23] | 12 | Epidermoid Adenocarcinoma | Yes | No | No | Response Progression | ↕ | ↕ | ↕ | ↕ |
Fraioli et al [24] | 45 | Adenocarcinoma | Yes | Bevacizumab | Response | ↓ | ↓ | |||
Lind et al [25] | 23 | Adenocarcinoma Epidermoid Large cell | Sorafenib Erlotinib | Response | ↓ | |||||
Tacelli et al [26] | 17 | Adenocarcinoma | Yes | Bevacizumab | Response | ↓ | ↓ | |||
Tacelli et al [26] | 23 | Adenocarcinoma Epidermoid Large cell | Yes | No | No | Response | ↔ | ↔ | ||
Sudarski et al [27] | 100 | Adenocarcinoma Epidermoid | Yes | No | No | Response Progression Stable | ↔ | ↔ | ↔ | ↔ |
Sudarski et al [27] | 100 | Small cell | Yes | No | No | Response Progression Stable | ↔ | ↔ | ↓ | ↔ |
Trinidad et al [current study] | 7 | Adenocarcinoma Epidermoid Large cell | Yes | Yes | No | Response | ↓ p > 0.05 | ↓ p > 0.05 | ↓ p > 0.05 | ↓ p > 0.05 |
Trinidad et al [current study] | 46 | Adenocarcinoma Epidermoid Large cell | Yes | No | No | Response | ↓ | ↓ |